Oncology Biomarkers Market Analysis Through 2030 Focusing On Demand Trends And Growth Drivers

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Are The Forecasted Market Size Figures For The Oncology Biomarkers Market In 2026 And 2030?

The oncology biomarkers market has experienced rapid expansion in its size over recent years. This market is projected to expand from $17.3 billion in 2025 to reach $19.73 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 14.1%. Historically, this growth has been fueled by several factors, including the wider implementation of cancer screening programs, progress in molecular biology research, the greater accessibility of biomarker testing platforms, an increase in oncology clinical trials, and enhanced cooperation between research institutions and hospitals.

The oncology biomarkers market size is anticipated to undergo significant expansion in the coming years. It is projected to achieve a valuation of $33.63 billion by 2030, progressing at a compound annual growth rate (CAGR) of 14.3%. This projected growth throughout the forecast period can be ascribed to several factors, including the escalating demand for personalized oncology therapies, the broadening scope of AI-driven biomarker discovery, increasing investments in cancer genomics, the rising embrace of liquid biopsy technologies, and a heightened focus on early cancer detection and monitoring. Noteworthy trends for the forecast period comprise the increasing integration of precision oncology diagnostics, the growing application of genetic and protein biomarkers, the expanding role of bioinformatics in biomarker analysis, the further development of companion diagnostics, and an intensified emphasis on individualized cancer treatment.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12493&type=smp

What Key Growth Drivers Are Influencing The Oncology Biomarkers Market?

The increasing occurrence of cancer is anticipated to drive the expansion of the oncology biomarker market in the future. Cancer is characterized by the uncontrolled proliferation of certain body cells, which gradually disseminate throughout the body. Oncological biomarkers offer deeper insights into cancer types by analyzing genes, proteins, and other bodily substances. For example, in February 2024, the Switzerland-based intergovernmental organization, World Health Organization, projected that by 2050, new cancer cases would exceed 35 million, marking a 77% surge from the estimated 20 million cases in 2022. Consequently, the growing prevalence of cancer is fueling the growth of the oncology biomarker market.

How Are Different Segment Groups Identified Within The Oncology Biomarkers Market?

The oncology biomarkers market covered in this report is segmented –

1) By Biomarker Type: Protein Biomarkers, Genetic Biomarkers, Other Biomarker Types

2) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Leukemia, Ovarian Cancer, Liver Cancer, Other Cancer Types

3) By Application: Diagnostics, Research And Development, Prognostics, Risk Assessment, Other Applications

4) By End-User: Hospitals, Academic And Cancer Research Institutes, Diagnostic Laboratories

Subsegments:

1) By Protein Biomarkers: Tumor-Specific Antigens, Circulating Tumor Cells (CTCs), Enzymatic Biomarkers

2) By Genetic Biomarkers: DNA Mutations, Gene Expression Profiles, Single Nucleotide Polymorphisms (SNPs)

3) By Other Biomarker Types: Metabolomic Biomarkers, Epigenetic Biomarkers, MicroRNA Biomarkers

Which Trends Are Influencing The Direction Of The Oncology Biomarkers Market?

Major companies in the oncology diagnostics market are concentrating on developing advanced biomarker-based assays to enhance early cancer detection, oversee minimal residual disease (MRD), and gauge patient responses to therapies. Minimal residual disease refers to the small quantity of cancer cells that might remain in the body following treatment, which could lead to recurrence if not identified. For example, in May 2024, Tempus, a US-based artificial intelligence and precision medicine firm, launched its portfolio of MRD tests, featuring the xM test and the xM (NeXT Personal Dx) test developed by Personalis. This collection includes both tumor-naïve and tumor-informed assays, designed to detect early cancer recurrence and residual disease, as well as to monitor patient reaction to immunotherapy. By harnessing circulating tumor biomarkers, these assays offer clinicians sensitive and actionable insights to guide patient management.

Which Companies Are Influencing The Oncology Biomarkers Market?

Major companies operating in the oncology biomarkers market are F Hoffmann-La Roche AG, Novartis AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Merck KGaA, Siemens Healthcare GmbH, Becton Dickinson and Company, GE Healthcare Technologies Inc., Eurofins Scientific SE, Agilent Technologies Inc., Hologic Inc., Illumina Inc., bioMerieux SA, Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN NV, Exact Sciences Corporation, Sysmex Corporation, PerkinElmer Inc., Leica Biosystems, Myriad Genetics Inc., Guardant Health Inc., Enzo Biochem Inc., Biocartis Group NV, Agendia Inc., Epigenomics AG, OncoDNA SA

Access The Complete Oncology Biomarkers Market Report:

https://www.thebusinessresearchcompany.com/report/oncology-biomarkers-global-market-report

Which Region Is The Primary Market For The Oncology Biomarkers Market?

North America was the largest region in the oncology biomarkers market in 2025. The regions covered in the oncology biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access a Oncology Biomarkers Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/report/oncology-biomarkers-global-market-report

Browse Through More Reports Similar to the Global Oncology Biomarkers Market 2026, By The Business Research Company

Cancer Biomarker Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report

Clinical Biomarkers Market Report 2026

https://www.thebusinessresearchcompany.com/report/clinical-biomarkers-global-market-report

Clinical Oncology Next Generation Sequencing Market Report 2026

https://www.thebusinessresearchcompany.com/report/clinical-oncology-next-generation-sequencing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795